New Report Reveals Growth Trajectories and Top Policy Factors Affecting Biopharmaceutical Innovation & Growth. New analysis incorporates real world insights from industry leadersContinue reading
Category Archives: AZBio News
Pfizer’s Ian Read succeeds Celgene’s Bob Hugin as PhRMA Board Chair
Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New PostsContinue reading
BioPharm Insight: Regenesis now sees exit as sale to strategic player in 12 to 24 months – CEO
Regenesis Biomedical, a Scottsdale, Arizona-based medical device company, now sees a sale to a strategic in 2015 or 2016 as its likely exit, said CEO Scott Brooks.Continue reading
Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduction
Capstone Therapeutics (OTCQB:CAPS) (“the Company”) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), announced today the initiation of dosing for its AEM-28 (Apo E mimetic peptide) Phase 1 human clinical trial in LDL/non-HDL cholesterol reduction.Continue reading
Arizona’s Bioscience Roadmap: 2014-2025 Unveiled
PHOENIX—The strategic plan that has guided Arizona’s fast-growing bioscience sector for nearly 12 years is gearing up for a new decade.Continue reading
HTG Molecular Diagnostics and OvaGene Oncology Partner on Gynecologic Cancer Tests
TUCSON, AZ–(Marketwired – Apr 7, 2014) – HTG Molecular Diagnostics, Inc., (HTG) and OvaGene Oncology have entered a manufacturing supply agreement where OvaGene will design and develop their proprietary gene expression assays on HTG’s fully automated, extraction-free Edge Platform.Continue reading
IMS Health Goes Public – IPO Raises $1.3 Billion
The IMS Health Holdings (NYSE:IMS) IPO represents the second-biggest IPO so far this year in the U.S.
IMS Heath’s IMS One portfolio of products includes 360 Vantage|IMS Health (Chandler, AZ). 360 Vantage was acquired by IMS Heath in May of 2013.
Phoenix moves closer to developing Arizona Biomedical Corridor near Mayo Clinic
The city of Phoenix is a step closer to developing the Arizona Biomedical Corridor near Mayo Clinic’s hospital in north Phoenix. Hear Mayo Clinic Arizona CEO Wyatt Decker talk about new corridor.
Ventana Signs Companion Diagnostics Agreement
Ventana signs companion diagnostic agreement with international biotech for antibody drug conjugate programContinue reading
Next Steps Announced in Advancing the ‘Arizona Biomedical Corridor’
Mayor Stanton and the Phoenix City Council Take Next Steps to Advance ‘Arizona Biomedical Corridor’
- Authorize $180 Million in Revenue Bonds to Finance Mayo Clinic’s Cutting-Edge Cancer Therapy Center
- Renew Agreement with ASU, Mayo Clinic to Develop Corridor
- State Land Dept. Will Auction Corridor Land by Year’s End